You have free access to this content

The Journal of Pathology

Cover image for Vol. 232 Issue 2

Special Issue: The Pathology of Drug Discovery

January 2014

Volume 232, Issue 2

Pages 99–282

Issue edited by: Adrian Jubb, Hartmut Koeppen, Jorge Reis-Filho

  1. Introductory Article

    1. Top of page
    2. Introductory Article
    3. Invited Reviews
    1. You have free access to this content
      Pathology in drug discovery and development (pages 99–102)

      Adrian M Jubb, Hartmut Koeppen and Jorge S Reis-Filho

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4290

  2. Invited Reviews

    1. Top of page
    2. Introductory Article
    3. Invited Reviews
    1. You have free access to this content
      Mouse tumour models to guide drug development and identify resistance mechanisms (pages 103–111)

      Meghna Das Thakur, Nancy K Pryer and Mallika Singh

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4285

    2. You have full text access to this OnlineOpen article
    3. You have full text access to this OnlineOpen article
      The evolving genomic classification of lung cancer (pages 121–133)

      David S Shames and Ignacio I Wistuba

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4275

    4. You have free access to this content
      New drug targets in metastatic melanoma (pages 134–141)

      Blanca Homet and Antoni Ribas

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4259

    5. You have free access to this content
    6. You have free access to this content
      Mechanisms of age-related macular degeneration and therapeutic opportunities (pages 151–164)

      Menno van Lookeren Campagne, Jennifer LeCouter, Brian L Yaspan and Weilan Ye

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4266

    7. You have free access to this content
    8. You have free access to this content
      Molecular pathology and prostate cancer therapeutics: from biology to bedside (pages 178–184)

      Daniel Nava Rodrigues, Lisa M Butler, David Lorente Estelles and Johann S de Bono

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4272

    9. You have free access to this content
      Pathology is a necessary and informative tool in oncology clinical trials (pages 185–189)

      Iris D Nagtegaal, Nicholas P West, J Han JM van Krieken and Phil Quirke

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4261

    10. You have free access to this content
    11. You have full text access to this OnlineOpen article
      Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (pages 199–209)

      Jérôme Galon, Bernhard Mlecnik, Gabriela Bindea, Helen K Angell, Anne Berger, Christine Lagorce, Alessandro Lugli, Inti Zlobec, Arndt Hartmann, Carlo Bifulco, Iris D Nagtegaal, Richard Palmqvist, Giuseppe V Masucci, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Michele Maio, Luigi Laghi, Fabio Grizzi, Martin Asslaber, Corrado D'Arrigo, Fernando Vidal-Vanaclocha, Eva Zavadova, Lotfi Chouchane, Pamela S Ohashi, Sara Hafezi-Bakhtiari, Bradly G Wouters, Michael Roehrl, Linh Nguyen, Yutaka Kawakami, Shoichi Hazama, Kiyotaka Okuno, Shuji Ogino, Peter Gibbs, Paul Waring, Noriyuki Sato, Toshihiko Torigoe, Kyogo Itoh, Prabhu S Patel, Shilin N Shukla, Yili Wang, Scott Kopetz, Frank A Sinicrope, Viorel Scripcariu, Paolo A Ascierto, Francesco M Marincola, Bernard A Fox and Franck Pagès

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4287

    12. You have free access to this content
      Developing biomarkers to predict benefit from HGF/MET pathway inhibitors (pages 210–218)

      Hartmut Koeppen, Sandra Rost and Robert L Yauch

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4268

    13. You have free access to this content
      Biomarkers of drugs targeting HER-family signalling in cancer (pages 219–229)

      Filippo Montemurro and Maurizio Scaltriti

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4269

    14. You have free access to this content
      The impact of germline mutations on targeted therapy (pages 230–243)

      Simon A Smith, Tim French and Simon J Hollingsworth

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4273

    15. You have free access to this content
      Somatic alterations as the basis for resistance to targeted therapies (pages 244–254)

      Brian G Blair, Alberto Bardelli and Ben Ho Park

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4278

    16. You have free access to this content
      Epistatic interactions and drug response (pages 255–263)

      Britta Weigelt and Jorge S Reis-Filho

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4265

    17. You have free access to this content
      Implications of intratumour heterogeneity for treatment stratification (pages 264–273)

      Andrew Crockford, Mariam Jamal-Hanjani, James Hicks and Charles Swanton

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4270

    18. You have free access to this content
      The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? (pages 274–282)

      Monica Arnedos, Philippe Vielh, Jean-Charles Soria and Fabrice Andre

      Version of Record online: 10 DEC 2013 | DOI: 10.1002/path.4276

SEARCH

SEARCH BY CITATION